Accessibility Menu
Spero Therapeutics logo

Spero Therapeutics(NASDAQ) SPRO

Market Cap$71.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-89%
5 Year-91%
1 Year-38%
1 Month-25%
$1.20
-2.85%
-0.04Today
After hours$1.19-$0.00 (-0.42%)
Spero Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.192026-08-17
Spero Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.25%USD 1.232026-08-10
1 month-24.68%USD 1.582026-07-17
3 month-54.05%USD 2.592026-05-19
Year to date-48.93%USD 2.332025-12-31
1 year-37.7%USD 1.912025-08-15
3 year-7.03%USD 1.282023-08-18
5 year-91.13%USD 13.422021-08-18
Since inception-89.3%USD 11.502017-11-02

Spero Therapeutics Financials at a Glance

Market Cap

$71.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$42.96M

Net Income (TTM)

$7.38M

EPS (TTM)

$0.11

P/E Ratio

11.26

Dividend

$0.00

Beta (Volatility)

0.93 (Low)

Price

$1.20

Volume

299,013.305

Open

$1.21

Previous Close

$1.19

Daily Range

$1.19 - $1.24

52-Week Range

$1.08 - $3.08

Estimated Earnings Date

Nov 12, 2026

SPRO News

rising chart chalkboard

Why Spero Therapeutics Stock Is Up 15% Today

James BrumleyJul 1, 2021
2 scientists in lab

Why Spero Therapeutics Shares Are Sliding Today

Keith SpeightsSep 11, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Spero Therapeutics

Spero develops oral antibiotics for hard-to-treat bacterial infections. Its main drug helps adults with complicated urinary tract infections.

What’s in the Spero Medicine Cabinet?

  • Tebipenem pivoxil hydrobromide (HBr): Oral antibiotic for adults with complicated urinary tract infections.
  • SPR720: Oral antibiotic for rare lung infections; development suspended in 2025.
  • SPR206: Intravenous drug for drug-resistant hospital infections; development discontinued in 2025.
  • Collaboration Revenue: Payments from partners like GSK for drug development milestones; main revenue source.
  • Grant Revenue: Funding from U.S. government agencies for research.

Growth Spurts and Strategic Moves

  • Partnered with GSK in 2022 to develop and commercialize tebipenem HBr outside Asia.
  • Signed licensing deals with Meiji Seika Pharma (tebipenem HBr) and Everest Medicines (SPR206) in Asia.
  • Collaborated with Bill & Melinda Gates Medical Research Institute for SPR720 lung infection research.
  • Restructured in October 2024, cutting workforce by 39% and focusing on tebipenem HBr.
  • Received $23.8 million milestone payment from GSK in Q3 2025, completing a $95 million development milestone.

Why Spero Stands Out (Without the Lab Coat)

Spero focuses on oral antibiotics for infections that usually require hospital IV drugs. Its business model relies on partnerships and government funding, not direct product sales. The company targets high-need areas where few oral treatments exist.

Five Things You Need to Know

  • Revenue was $12 million in Q2 2025, up 96.1% from Q2 2024.
  • Net loss was $2 million in Q2 2025, improving 87.2% year-over-year.
  • Tebipenem HBr accounted for 83.1% of Q2 2025 revenue.
  • Cash and equivalents were $31.2 million as of June 30, 2025.
  • Full-time employees numbered 32 at the end of Q2 2025.

Bottom Line

Spero has shifted to focus on one main oral antibiotic and partnerships. Its business depends on milestone payments and government grants, not product sales.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

25

CEO

Esther Rajavelu, MBA

Website

www.sperotherapeutics.com

Headquarters

Cambridge, MA 02139, US

SPRO Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

14.02%

Net Income Margin

17.18%

Return on Equity

16.17%

Return on Capital

-0.04%

Return on Assets

13.99%

Earnings Yield

8.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$71.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

58.23M

Volume

299.01K

Avg. Volume

1.60M

Financials (TTM)

Gross Profit

$42.96M

Operating Income

$6.03M

EBITDA

$7.70M

Operating Cash Flow

$19.58M

Capital Expenditure

$0.00

Free Cash Flow

$19.58M

Cash & ST Invst.

$50.77M

Total Debt

$2.04M

Spero Therapeutics Performance Analysis

Spero Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 48,579,0001482.4%
20232023-12-31USD 96,735,00099.1%
20242024-12-31USD 27,396,000-71.7%
20252025-12-31USD 59,619,000117.6%
Spero Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-74.2%
Q42025-12-311201.1%
Q12026-03-31-99.3%
Q22026-06-30-100.0%
Spero Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.23-57.5%
20232023-12-31USD 0.43N/A
20242024-12-31USD -1.27N/A
20252025-12-31USD 0.15N/A
Spero Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-329.0%
Q42025-12-31507.7%
Q12026-03-31-124.5%
Q22026-06-30-23.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$71.63MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.87M

N/A

Employees

25

N/A

Net Income

-$9.55M

-461.9%

EBITDA

-$9.55M

-304.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$50.77M

+62.8%

Total Debt

$2.04M

-43.5%

Accounts Receivable

$25.00K

-99.9%

Inventory

$0.00

N/A

Long Term Debt

$43.00K

-97.6%

Short Term Debt

$2.00M

+8.5%

Return on Assets

13.99%

N/A

Return on Invested Capital

13.59%

N/A

Free Cash Flow

-$5.36M

+69.7%

Operating Cash Flow

-$5.36M

+69.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INOInovio Pharmaceuticals, Inc.
$1.15+5.50%
CGTXCognition Therapeutics, Inc.
$1.02+0.99%
MCRBSeres Therapeutics, Inc.
$4.51-0.66%
SEERSeer, Inc.
$2.03-2.40%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.61-0.02%
SPCXSpace Exploration Technologies
$146.23+0.04%
IPSTIp Strategy
$7.39+2.36%
NVDANvidia
$225.01-0.00%

Questions About SPRO

What is the current price of Spero Therapeutics?

Spero Therapeutics is trading at $1.19 per share.

What is the 52-week range for Spero Therapeutics?

Over the past 52 weeks, Spero Therapeutics has traded between $1.08 and $3.08.

How much debt does Spero Therapeutics have?

As of the most recent reporting period, Spero Therapeutics reported total debt of $2.04M.

How much cash does Spero Therapeutics have on hand?

Spero Therapeutics reported $50.77M in cash and cash equivalents in its most recent financial results.

What is Spero Therapeutics’s dividend yield?

Spero Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services